Division of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Bronx, NY, USA.
Haemophilia. 2013 Nov;19(6):814-26. doi: 10.1111/hae.12145. Epub 2013 Apr 22.
Factor XIII (FXIII) deficiency is a rare bleeding disorder, which can result in life threatening hemorrhage. Rarer still is acquired FXIII deficiency, in which the disorder is due to autoantibodies that inhibit the factor. To describe one of the youngest reported patients with this condition. To discuss the challenges we encountered in monitoring response with the available assays. To review the literature and provide a review of all acquired FXIII cases. We present the case of our patient, a 9-year-old girl with acquired FXIII deficiency. We present a comprehensive review of all acquired FXIII deficiency cases reported globally in English, with focus on clinical presentation, diagnostic assays, treatment and prognosis. There is no current standard for therapy and measuring response to therapy can be complicated by limitations of assays in the presence of inhibitors. Clinicians should be aware of acquired FXIII deficiency as a potentially life threatening bleeding disorder even in young children. The case presented illustrates a young patient with acquired FXIII deficiency with a good clinical response to cryoprecipitate and difficulty in hemostasis monitoring utilizing clinically available assays.
凝血因子 XIII(FXIII)缺乏症是一种罕见的出血性疾病,可能导致危及生命的出血。更为罕见的是获得性 FXIII 缺乏症,其病因是由于自身抗体抑制了该因子。描述其中一位有记录以来最年轻的患者。讨论我们在使用现有检测方法监测反应时遇到的挑战。回顾文献并对所有获得性 FXIII 病例进行综述。我们介绍了一位 9 岁女孩的病例,她患有获得性 FXIII 缺乏症。我们全面回顾了全球用英文报道的所有获得性 FXIII 缺乏症病例,重点关注临床表现、诊断检测、治疗和预后。目前尚无标准的治疗方法,由于抑制剂的存在,检测方法的局限性可能使治疗反应的测量变得复杂。临床医生应该意识到,即使是在儿童中,获得性 FXIII 缺乏症也是一种潜在的危及生命的出血性疾病。所呈现的病例说明了一位年轻患者患有获得性 FXIII 缺乏症,对冷沉淀治疗有良好的临床反应,但在使用临床可用的检测方法监测止血方面存在困难。